Case T- 691/14 Servier v Commission et al (pay–for–delay) [Archived]
Case T- 691/14 Servier v Commission et al (pay–for–delay) [Archived]

The following Competition guidance note provides comprehensive and up to date legal information covering:

  • Case T- 691/14 Servier v Commission et al (pay–for–delay) [Archived]
  • Case facts
  • Timeline
  • Commentary
  • Related cases

ARCHIVED—this achieved case hub reflects the position at the date of the decision of 12 December 2018; it is no longer maintained.

NOTE—appeals lodged before the Court of Justice in Cases C- 144/19 P, C- 151/19 P, C- 164/19 P, C- 166/19 P, C- 176/19 P, C- 197/19 P, C- 198/19 P, C- 201/19 P and C- 207/19 P

See further: timeline and commentary.

Case facts

Outline Appeals to the General Court in seeking annulment and/or reductions in the level of fines imposed regarding the Commission’s decision of 9 June 2014 finding infringements of Article 101 and Article 102 insofar as they relate to Servier and imposing fines totalling €427.7m on Servier and five producers of generic drugs to delay the entry of perindopril.

Outcome On 12 December 2018, the General Court issued its judgments in Cases T- 691/14 Servier v Commission, T- 677/14 Biogaran v Commission, T- 679/14 Teva UK and Others v Commission, T- 680/14 Lupin v Commission, T- 682/14 Mylan Laboratories and Mylan v Commission, T- 684/14 Krka v Commission, all actions for the annulment of the Commission’s decision finding an infringement of Articles 101 and 102 TFEU by Servier and five generic
Navigate the law quickly and efficiently with Lexis®PSL
Imagine being able to quickly find up-to-date guidance on points of law and then easily pull up sources to support your advice. With LexisPSL, you can.
Take a free trial Take a free trial
Related documents: